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Summary.-Cis-dichlorobis(cyclopentylamine)platinum II (DBCP) belongs to the
group of platinum complexes which have recently been reported to have anti-tumour
activity. Its cytotoxic activity in CHO cells is not cell-age-dependent, but enhance-
ment of the effect of ionizing radiation is both dose-and cell cycle phase-dependent.
In asynchronous cell populations DBCP acts as a dose-modifying factor for ionizing
radiation. Doses of DBCP reducing survival of CHO cells to 26% and4% applied 1 h
before irradiation reduce the Do value of radiation dose-survival curves by factors of
1-34 and 1 59 respectively.
In synchronized CHO populations enhancement by DBCP of the effect of radiation
is most pronounced in G1 and in late S while it is reduced in mid-S. Possible
mechanisms of DBCP-radiation interaction are discussed.
PLATINUM complexes were reported by
Rosenberg et al. (1969) to have antibiotic
and antitumour activities. Several years
later one of the simplest inorganic Pt
complexes, cis-dichlorodiammine platinum
(II) (cis-DDP) has been reported to be
effective in the treatment of some human
cancers (e.g. Rossof, Slayton and Perlia,
1972; Wallace and Digby, 1974; Wiltshaw
and Carr, 1974). In 1972, Connors et al.
synthesized a series of organic platinum
complexes, some ofwhich had significantly
higher therapeutic indices than cis-DDP
with a plasma-cell tumour in mice.
One of these is cis-dichlorobis(cyclo-
pentylamine)platinum (II), or DBCP.
The structure of this coordination com-
plex is shown in Fig. 1 which depicts
H2
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/Pt
N: \CI
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F1(.m. . Stru4icture of cis-dichlorobis(cyclo-
penltylamnine)platinum II (DBCP).
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cis-chlorides, planar platinum (II) and
two dative coordinate bonds whereby the
lone pairs on the primary amines are
donated into the metal's orbitals.
A therapeutic index of 235 7 was
obtained for DBCP, a value nearly 30
times higher than that for the cis-DDP
(Connors et al., 1972). This high value
encouraged studies of the effect of DBCP
at the cellular level in an in vitro system
(Szumiel and Nias, to be published). It
was found that (similarly to other Pt
complexes studied in other cell culture
systems) DBCP inhibits synthesis of DNA
in CHO cells. It also interferes with
G- S transition and progress through
G1 and G2 phases during the first 12 h
after treatment and inhibits cell growth by
causing lethal as well as non-lethal
damage.
The mechanism ofcytotoxic activity of
Pt complexes is not yet fully understood.
It was therefore rather difficult to predict
the effect of DBCP pretreatment on the
response ofCHO cells to ionizing radiation.
However, bearing in mind the importance
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of drug-radiation interaction for cancer
treatment and considering the encouraging
report on cis-DDP-x-ray interaction in
vivo (Wodinsky et al., 1974), a study was
undertaken to characterize the effects of
combined treatment with DBCP and
radiation on CHO cells.
MATERIALS AND METHODS
Cell culture. Chinese hamster ovary
(CHO) cells were cultured in disposable
plastic tissue-culture flasks (Falcon): T75
for stock cultures and chromosome experi-
ments, T30 for radiation experiments.
HEPES-buffered (20 mM) Ham's F12
medium (supplemented with 160o calf serum,
non-essential amino-acids and 2 mM
glutamine) was prepared with 2 different
concentrations of Na+ and Cl- ions, using
Ham's F12 concentrated (10x) solution. All
medium components were supplied by Gibco-
Biocult Ltd. During the period of these
studies the concentration of Na+ and Cl- ions
was altered by the suppliers. The original
medium (A) contained 106 mM Na+ and
108 mM Cl1: the new medium (B) 119
mM Na+ and 120 mM Cl-. The doubling
time of CHO cells in both media was 11-5-
12-0 h.
Methods of cell culture were described in
detail previously (Nias, 1968). All treat-
ments were administered after the cells had
adhered to the surface of the flasks.
Irradiation.-The 60Co y-ray exposures
were carried out using an Orbitron therapy
unit, with a dose-rate of 120 rad/min. For
later experiments 250 kVp x-irradiations
were carried out with a Stabilipan Unit,
adapted for cell irradiation. The half-value
layer was 1-85 mm Cu, and the dose-rate was
130 rad/min.
Curve fitting.- The dose-survival curves
for radiation only were fitted by the least
squares method; the curves obtained for
combined treatment were drawn by eye from
a common extrapolation number.
The data points are shown as mean values
(from at least two experiments per point)
+ the standard error of the mean.
Platinum complex.-Cis-dichlorobis(eyclo-
pentylamine)platinum II (DBCP) was
kindly provided by Dr T. A. Connors and
Johnson Matthey & Co. Ltd.
Treatment with DBCP.-This will be des-
cribed in detail elsewhere (Szumiel and Nias,
to be published). Cells were exposed to the
drug for a period of 1 h at 37°C.
Synchronization.-Synchronized CHO cell
populations were obtained by the initotic
selection method (Terasima and Tolmach,
1963). In order to estimate the degree of
synchronization, determinations wAere made
of the mitotic index at zero time, and of
average cellular multiplicity and labelling
index at 1 h intervals. The mitotic index
was 950o or higher in all the experimnents
reported.
Auatoradiography. This was carried out,
and will be described elsewhere (Szumiel and
Nias, to be published).
Chromosomepreparations. The procedure
was essentially that ofMoorhead et al., (1960)
except that hypotonic treatment wsas carried
out in 0-7o sodium citrate for 13 min at
37°C. Details of the procedure applied will
be given elsewhere (Szumiel and Nias, to be
published). About 100 cells w-ere analvsed
for each method of treatment.
RESULTS
Combination of DB(R.P and radiation in
acsynchronou-s (CHO cell popualations
The response of CHO cells to [)BCP
treatment alone was found to be depen-
dent on the composition of the medium
used (Szumiel and Nias, to be puiblished).
This is illustrated by the data in Table I.
Combination of DBCP and radiation
was investigated in both A and B medium
using either y- or x-rays. Fig. 2 shows 2
examples ofDBCP-radiation combination:
(a) DBCP-y-rays in medium A (b) DBCP-
x-rays in medium B. In these experi-
ments DBCP treatment (for 1 h at 37°C)
was followed by irradiation after the cells
were maintained for a further 1 h interval
at 37°C.
In both examples the survival data, for
combined treatment are normalized to
survival after DBCP treatment alone.
Thus, if there was only an additive effect
of both agents the dose-survival curve for
combined treatment would be stuper-
imposed on the curve obtainedl for
radiation alone. As may be seen in Fig. 2
there is a clear difference between the
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TABLE L.-Dose-survival Curve Parameters Obtained for DBCP Treatment
of CHO Cells in Two Media
Concentration Dose-survival curve parameters*
in the medium DBCP ,i -
r - Alife Do DQ
Medium Na+ CI- (min) (sg/ml) (/ug/ml) N
A 106 mM 108 mM ca 160 9 3 17-5 6-7
B 119 mM 120 mM ca 45 14-0 27-5 7 3
* Treatment for 1 h at 37'C. (Data from Szumiel and Nias, in the press)
Dose-Modifying
Factor
A
O
A
Surviving
Fraction
DOSE(rod)
FIG. 2.-Dose-survival curves obtained for
CHO cells irradiated with or without prior
DBCP treatment. Mean values from 4
experiments; standard errorindicated unless
smaller than the point drawn. (a) medium
A; A, y-rays alone, Do= 160 rad; 0, 26
,ug/ml (1 h, 37°C) ofDBCP given 1 h before
irradiation, Do = 130 rad; (b) medium B;
A, x-raysalone, Do = 170rad; 0, 46 Msg/ml
(1 h, 37'C) of DBCP given 1 h before
irradiation, Do = 127 rad.
final slopes in each pair of curves, although
there is no significant difference between
the extrapolation numbers. The ratio of
the respective Do values (i.e. the dose-
modifying factor) is 1-23 in medium A
and 1-34 in medium B. These relatively
similar values, however, were obtained for
DBCP Dose(tug/ml,lh,
FIG. 3.-Relationship between DBCP dose
and the dose-modifying factor determined
for combined treatment (DBCP 1 h before
irradiation) in 2 kinds of media. Symbol A
represents results from both y-rays and
x-rays.
different concentrations of DBCP used
for pre-treatment.
Results offurther experiments indicate
that the value of the dose-modifying
factor depends on the position on the
dose-survival curve to which survival is
reduced by DBCP pre-treatment alone
and this is the reason for the differences
found when using media A and B. This
is shown in Fig. 3: in medium A a dose of
26 jig/ml of DBCP reduces survival to
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1
2
3
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5
6
74 72 26 24 6 4 2 0 2
74 72 26 24 6 4 2 2 , , I ,//° r l ,t,/ *Fl,I
74 72 26 24 6 4 2 0 2
74 72 26 24 6 4 2 0 2
74 72 26 24 6 4 2 0 2
74 7 26 24 6 '4. 2 '0 2
Time (h)
OPLATING, * REPLATING, 42 BEGINNING of DBCP TREATMENT,
I DURATION of DBCP TREATMENT, i IRRADIATION.
FIG. 4. Diagram showing the timing of the 6 combinations of DBCP-radiation treatment of CHO cells.
390/0 which is on the exponential part of
the curve-and it clearly enhances the
effect of radiation. However, the same
dose in medium B only reduces survival to
55% (on the shoulder of the curve) and
there is no enhancement of the effect of
radiation. The dose of 33 ,ug/ml is still
within the shoulder and again no enhance-
ment is seen. The next higher dose
(46 ,ug/ml) is on the exponential part of
the curve (survival, 26%) and, when used
for pre-treatment, gives a dose-modifying
factor of 1-34. An even higher value
(1-59) is obtained for 72 ,ug/ml ofDBCP in
medium B.
The effect of other intervals between
DBCP treatment and irradiation was also
investigated: the timing used in the 6
experimental protocols is shown diagram-
matically in Fig. 4 and the results are
tabulated in Table II. With 72 h and
24 h intervals between DBCP pre-treat-
ment and irradiation no enhancement was
found. With shorter intervals the dose-
modifying factor was much the same
value, independently of the sequence of
DBCP-radiation administration or kind of
medium, with both y- and x-rays. There-
fore, it seems that Cl-O cells need more
than 4 h but less than 24 h to remove
DBCP bound to the target molecules.
However, no data are available on the
TABLE II. Reisults ofthe Six Combinations
of DBCP-radiation Treatment of CHO
Cells Depicted in Fig. 4
DBCP Dose
Medium pg/ml, 1 h, 37°C
2
3
4
5
6
A
A
A
B
A
B
B
A
26
26
26
46
26
46
46
26, 33, 46
Dose
modifying
Radiation factor
y 1
y 1
y 1-29
x 1-52
y 1-23
x 1-34
y 1-33
y 1-15
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Surviving Fraction
10-
\ 4
I Non-irradiated
0-1- \t\+ ~~~~Do =9-5pg/ml
300 rad 6-rays \ u
before drug treatment
Do = 8,g/ml 1\ \
Relative Survival
0-001 i I
0-01-
0 20 40 60
Drug Concentration (pg/mI for 1h)
FIG. 5. Dose-survival curves obtained for
CHO cells DBCP-treated with or without
prior y-irradiation. Mean values from 4
exxperiments; standard error indicated.
fate of Pt complexes in recovering cells
except that when the DBCP dose was
applied 2 h after irradiation the inter-
action was less pronounced. In Fig. 5 the
cell response to 3 doses of DBCP is com-
pared with the response for combined
treatment, survival data being normalized
to survival after irradiation alone. For
this experimental schedule the dose-
modifying factor of 1.15 was obtained.
Effect of DBCP pretreatment on split-dose
irradiated CHO cells
As may be seen in Fig. 2, treatment
with DBCP reduces the Do and the DQ in
Interval Between Doses( hI
FIG. 6. Relative survival of CHO cells sub-
jected to split-dose y-irradiation alone or
preceded,byDBCP treatment. Mean values
from 2 experiments, with standard error in-
dicated unless smaller than thepoint drawn.
the radiation dose-survival curves al-
though common extrapolation numbers
were found. It was nevertheless possible
that a decrease in the sparing effect of
split-dose irradiation could be expected in
DBCP-pre-treated CHO cells. Indeed, as
shown in Fig. 6, pre-treatment with 26
jtg/ml of DBCP (in medium A) 1 h before
the first of two doses of 300 rads ofy-rays
reduces relative survival (at the maximum
level) from 2 to 1 6. Survival level at
zero interval (i.e. after 600 rads) is
normalized to 1.
Combination of DBCP and radiation in
synchronous CHO cell populations
In order to throw further light upon
the mechanism of interaction of DBCP
with radiation, experiments on synchron-
ized CHO cell cultures were carried out.
It was found previously (Szumiel and
Nias, to be published) that DBCP is not a
phase-sensitive drug while x-radiation
gives a cell-stage-response with a mini-
mum survival level in G1 and a maximum
in mid-S with CHO cells.
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Fig. 7 shows the stage-response
patterns obtained for 450rad of x-rays
and 46 ,tg/ml of DBCP separately.
In further experiments synchronized
CHO populations in G1, mid-S and late-
S phases were subjected to treatment with
Surviving
Fraction
Labelled
Cells
(o)
Time After Cell Harvest (h)
FIG. 7.-Stage-response patternsforCHO cells
irradiated with 450 rad of x-rays or treated
with 46 jug/ml of DBCP (1 h, 37°C). Mean
values from 3 experiments; standard error
indicated, unless smaller than the point
drawn.
Mitotic
Selection
Sub-
Culture
18h 0 _ _ _ _ 1+5
46 ,ug/ml of DBCP and, after 1 h, irradi-
ated with 450 rad of x-rays. The design
of the experiment is shown in Fig. 8.
The survival data are shown in Table III.
The percentage survival that would be
expected for additive action is compared
with that obtained and the ratio of
observed to expected values is taken as a
measure of the enhancement of x-ray
effect by DBCP. With the ratio ofunity,
there is no interaction between these
agents: the lower the ratio, the greater the
enhancement. As may be seen in Table
III, DBCP enhances the effect ofx-rays to
the greatest extent in the G1 phase and
slightly less in late-S, while in mid-S the
effect is closer to additive.
Effect of DBCP treatment on the yield of
chromatid aberrations in x-irradiated CHO
cells
In order to examine the effect of
DBCP treatment on the formation of
TABLE III.-Interaction of Pt Complex
with x-irradiation in Synchronized CHO
Populations in Termrs of % Survival of
Treated Cells
% Expected
(additive)
% Observed
Observed
Expected
Time(h)
GI Mid-S Late-S
4-50±0-40 10-20±0-70 7-70±0-10
1*80±0-15 6-70±0-36 3*35±0 05
0-40±0-01 0-66±0-01 0-43±0-09
6 8 10
I I I
Late
S
d
Beginning and L Duration of DBCP Treatment X-lrradiation
FIG. 8.-The design of experiment for combined treatment of synchronized CHO cells (46,ug/ml,
1 h, 370: 1 h interval: 450 rad x-rays, medium B).
a I a
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chromatid aberrations in CRO cells the
following experiment was designed: 2 h
after plating, asynchronous cells were
treated with 46 ,tg/ml of DBCP (1 h,
37°C, in medium B) and after 1 h interval
-irradiated with 450 rad of x-rays.
Three hours after irradiation colchicine
was added and, after a further 2 h in-
cubation, mitotic cells were shaken offand
used as material for chromosome prep-
arations. With this timing, and the
duration of the S and G2 phases being
about 8 h and 2 h respectively, the
mitotic cells harvested would be those
irradiated in late S and G2 phases and
subsequently arrested for about 4 h in G2
phase because of mitotic delay. Cells
treated with DBCP only were those
which were in mid-S phase at the time of
treatment. Results obtained are pre-
sented in Table IV.
As may be seen, DBCP alone produced
a very small number of chromatid aber-
rations 6 h after the end of treatment.
This is understandable since cells were
treated with DBCP in the mid-S phase and
the mechanism of formation of chromo-
somal aberrations after drug treatment
is of the so-called "delayed" type
(Kihlman, 1966), dependent on DNA
synthesis. It involves replication of the
damaged (cross-linked) DNA and form-
ation of gaps opposite the damaged sites.
These gaps are subsequently filled by de
novo synthesis.
DBCP combination with radiation
increased the yield of chromatid aber-
rations more than additively. The in-
crease would be more than additive even
ifthe cells had been treated with DBCP in
G1 phase: in a separate experiment on
synchronous CHO cells DBCP (46 ,ag/ml,
1 h, 37°C, medium B) was applied in G1
and 13-5 chromatid aberrations per 100
cells were scored in the first mitosis after
treatment and 25-2 in the second mitosis
(Szumiel and Nias, to be published).
The data in Table IV indicate that
DBCP pre-treatment increases the fre-
quency of chromatid aberrations in cells
irradiated in late S and G2, the potenti-
ation factor (Kihlman et al., 1974) being
2-2.
With the experimental procedure
applied, only part of the asynchronous
population could be studied and, there-
fore, no conclusion can be drawn on the
relation ofchromosomal aberrations to the
lethal effect of combined treatment.
However, it is obvious that unrepaired
DBCP-induced damage interferes with
repair of radiation damage, and the
existence of such a direct relation seems
possible.
DISCUSSION
There are several rationales for select-
ing cytotoxic drug combinations, which
can also be applied to combinations
of radiation and drugs. One of the
possibilities is to combine two agents
having their maximal lethal effects on
cells in different phases of the cell cycle.
Good examples of a combination of this
kind are actinomycin D and x-rays
(Elkind, Sakamoto and Kemper, 1968)
and high concentration of methotrexate
followed by x-irradiation (Berry, 1968).
Since DBCP is not a phase-specific drug,
TABLE IV. Chrornatid Aberrations in CHO Cells Treated with
DBCP and x-rays Separately or in Combination
CH() cells
Control
DBCP-treated (46 /ig/ml)
X-irradliatecl (450 rad)
After combined treatment
(46 ,tg/ml + 450 rad)
Surviving
Chromatid aberrations per 100 cells fraction for
- t,he treatmenit
Gaps and breaks Exchanges appliedt
<1 <1 1
4-4 <1 0 26
101 98 0-18
239 216 0 03
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this kind of interaction cannot contribute
to the cytotoxic activity of DBCP-x-ray
treatment.
Another possibility is to combine an
agent which slows cell progress through a
particular phase of the cell cycle (not by
means of a lethal effect) with a second
agent that is maximally lethial in that
phase (e.g. a non-lethal concentration of
methotrexate and radiation, Berry, 1968).
It has been shown (Szumiel and Nias, to be
published) that DBCP treatment slows
down the rate of DNA synthesis, decreas-
ing at the same time the number of cells
entering S phase. Therefore, the mechan-
ism of DBCP-x-ray interaction, observed
in the G1 phase (Table III) could depend
partly on inhibiting the G,1 S progres-
sion and arresting cells in the radiation-
sensitive G1 phase. This assumption is
justified by labelling data obtained in the
experiments described in Fig. 8: mean
labelling index obtained at 3 5 h (i.e. time
of irradiation of 1P5 h-DBCP-pre-treated
samples) is 35%0 for control cells and 20%
for DBCP-pre-treated cells. Since in the
sparing effect of split-dose irradiation the
"cell progress" component is significant,
this mechanism could provide an explan-
ation for the results of the DBCP-x-ray
split-dose experiment (Fig. 6).
One can speculate that inhibition of
the G1 --+S progression might be due to a
rise in the cAMP level, and such a rise has
been found after cis-DDP treatment
(Tisdale and Phillips, 1 975a). Alkylating
agents were reported to have that effect on
Walker carcinoma cells (Tisdale and
Phillips, 1975b) and the increase of intra-
cellular cAMP was found to be directly
related to growth inhibition in 2 lines of
Walker ascites carcinoma 256, resistant
and sensitive to alkylating agents. It
was found (Connors, 1974) that Walker
carcinoma cells differing in resistance to
alkylating agents also differ in their
resistance to cis-DDP. Thus, it is possible
that one of the cell responses to a Pt
complex treatment (in fact a common
response to a wide range of stimuli) is a
change of cAMP level: this, in most cell
lines, is the cause of arrest of growth by
inhibition of nucleic acid synthesis (Lim
and Mitsunobu, 1972).
This kind ofexplanation could be valid
of course only for the type of experiments
where DBCP treatment was given prior to
radiation. However, the survival data
presented suggest that the presence of
DBCP inside the cells is not needed to
produce an enhancement of the effect of
radiation, since DBCP treatment 2 h after
irradiation can still decrease the cell
survival in a more than additive manner,
although the effect is less pronounced than
in DBCP pre-irradiation. This means
that DBCP may be regarded as analogous
to those radiation sensitizers which can be
added after irradiation and then interfere
with processes leading to cell recovery.
A general principle of the interaction
of two agents producing lethal effects by
damage of the same target would be that
lesions caused by the first agent which are
only potentially lethal (using the words
"potentially lethal" in a general sense) are
converted into lethal lesions by action of
the second agent. Thus, the most obvious
assumption would be that DBCP inter-
feres with post-irradiation DNA repair.
Pt complexes are known to cross-link DNA
(Roberts, 1974) and this kind of lesion is
repaired most probably by a post-
replication type mechanism, whilst the
radiation lesions are mostly repaired by
rejoining of the single-strand breaks. By
creating a steric hindrance (cross-linking)
for this repair process DBCP could
enhance the number of misrepaired and/or
unrepaired radiation lesions even when
applied after irradiation. The reverse
can also be true: i.e. radiation lesions can
interfere with repair of DBCP-damage.
In fact, the results of an experiment
(Fig. 5) where radiation was applied prior
to DBCP can be interpreted as showing a
radiation-induced sensitization of CHO
cells to DBCP.
It is usually assumed that misrepair
leads to non-lethal or lethal mutations,
while unrepaired DNA breaks can be
visualized at the cytological level as
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chromosomal aberrations, during mitosis
preceding reproductive death. It seems
that DBCP disturbs the repair processes,
leaving a higher number of DNA breaks
unrepaired, since DBCP applied prior to
radiation significantly increases the yield
of chromatid aberrations in a clearly
synergistic manner (Table IV). More-
over, in the experimental system used, the
late-S cells were more readily killed with
drug-radiation combination than mid-S
cells (Table III). This is in accord with
the data recently published by Burki
(1974), who found that late-replicating
chromatin is much more sensitive to
ionizing radiation than early-replicating
chromatin.
In the light of the present state of
knowledge of Pt complexes, DBCP is
acting on the same principle as other
antitumour platinum compounds, with
DNA as the main target molecule. Al-
though there are many steps between in
vitro experiments and clinical practice, the
results reported here allow one to consider
the possibility of obtaining an improved
therapeutic ratio by combined treatment
with Pt complexes of high antitumour
selectivity and low-LETionizingradiation.
The authors are grateful for the
technical assistance ofMrs SheilaMcEwan.
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